Torrent Pharmaceuticals posts Q1 FY 24 consolidated PAT at Rs. 378 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2625 crores during the period ended June 30, 2023

Gland Pharma posts Q1 FY24 consolidated PAT at Rs. 194.10 Cr

Gland Pharma has reported total income of Rs. 1246.23 crores during the period ended June 30, 2023

Surging demand for Korean pharma in 2023 ahead of CPHI Korea

Pharma in Korea receives a 7% increase in ‘growth potential’ category according to the CPHI Annual Survey findings

USFDA concludes inspection at Solara's Cuddalore facility with Zero 483 inspectional observations

Tatva Chintan Pharma Chem posts Q1 FY24 consolidated PAT at Rs. 9.50 Cr

The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023

Fortis Healthcare Q1 FY24 consolidated PAT drops at Rs. 111.76 Cr

Fortis Healthcare has reported total income of Rs. 1665.55 crores during the period ended June 30, 2023

Indraprastha Medical Corporation Q1 FY24 PAT up at Rs. 30.50 Cr

The company has reported total income of Rs. 310.07 crores during the period ended June 30, 2023

Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP

The product is being launched in August 2023

Granules Pharmaceuticals successfully completes USFDA post marketing adverse drug experience inspection with zero observations

The inspection was conducted at Granules Pharmaceuticals Inc. (GPI) from July 31, 2023 to August 03, 2023

USFDA approves Merck’s ERVEBO for use in children 12 months of age and older

Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease